the Alvarado Hospital, San Diego, CA.
the Endo Pharmaceuticals Inc., Malvern, PA.
Urology. 2020 Dec;146:145-151. doi: 10.1016/j.urology.2020.08.045. Epub 2020 Sep 4.
To examine the long-term (5-year) efficacy and safety of collagenase clostridium histolyticum (CCH) therapy in men with Peyronie's disease and varying degrees of plaque calcification.
CCH-treated adult men from the 12-month Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies I/II or 9-month open-label studies were eligible. Degree of plaque calcification (no calcification, noncontiguous stippled calcification, or calcification that did not interfere with CCH injection) was determined by penile x-ray or ultrasound. Penile curvature deformity and Peyronie's Disease Questionnaire responses were assessed annually for up to 5 years, with ≥6 months between consecutive visits.
For no calcification group, from baseline to last (Reference) visit during the prior studies (n = 160), mean penile curvature improved by 20.9° ± 16.3° (39.3%) with CCH. Similar improvements with CCH from baseline to Reference were observed in stippled calcification (n = 27; improvement of 24.1° ± 20.2° [42.7%]) and calcification (n = 27; improvement of 21.7° ± 14.8° [43.3%]) subgroups. At Year 5 follow-up in no calcification group (n = 119), an additional 10.0% improvement in mean penile curvature vs Reference (4.3°) occurred. Penile curvature improvements seen at Reference in stippled calcification and calcification groups were maintained through Year 5. Additional numeric improvements in 3 Peyronie's Disease Questionnaire domains were observed at Year 5 visit vs baseline scores. No long-term safety issues were identified.
This first report of long-term (5-year) CCH clinical trial outcomes in a population with penile plaque calcification demonstrates that nonsurgical intralesional CCH therapy is an appropriate Peyronie's disease treatment in men with penile plaque calcification that is stippled or does not impede CCH injection.
研究在不同程度斑块钙化的情况下,应用胶原酶溶组织梭菌(CCH)治疗男性 Peyronie 病的 5 年长期疗效和安全性。
来自 12 个月的最大 Peyronie 减少疗效和安全性研究 I/II 或 9 个月开放标签研究的接受 CCH 治疗的成年男性符合入选条件。通过阴茎 X 线或超声确定斑块钙化程度(无钙化、点状钙化或不干扰 CCH 注射的钙化)。在长达 5 年的时间里,每年评估阴茎弯曲畸形和 Peyronie 病问卷的反应,连续就诊之间至少间隔 6 个月。
在无钙化组中,在先前研究的基线至最后(参照)访视(n=160)期间,CCH 治疗后阴茎弯曲改善了 20.9°±16.3°(39.3%)。在点状钙化(n=27;改善 24.1°±20.2°[42.7%])和钙化(n=27;改善 21.7°±14.8°[43.3%])亚组中,从基线到参照,也观察到了类似的 CCH 改善。在无钙化组的 5 年随访中(n=119),参照时平均阴茎弯曲的进一步改善为 10.0%(4.3°)。点状钙化和钙化组参照时观察到的阴茎弯曲改善情况在 5 年内得以维持。与基线评分相比,在第 5 年就诊时,3 个 Peyronie 病问卷领域的额外数值改善得到了观察。未发现长期安全性问题。
这是首次报道在存在阴茎斑块钙化的人群中进行的 5 年 CCH 临床试验结果,表明非手术腔内注射 CCH 治疗是一种合适的治疗方案,适用于点状或不阻碍 CCH 注射的阴茎斑块钙化的男性 Peyronie 病患者。